ClinicalTrials.gg
CompletedNCT02180321Updated Apr 12, 2016

Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled Trial

An interventional study of Tranexamic Acid and normal saline in Craniosynostosis Patients Undergoing Distraction Osteotomy, sponsored by Yonsei University. Completed at 1 site in Korea, Republic of. Open to participants aged Up to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-12.

Sponsored by Yonsei University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
Up to 6 Years
Sex
All
01

Study summary

Massive bleeding is expected when performing distraction osteotomy for craniosynostosis patients. Since such operation is performed at very young age, many efforts are performed in order to reduce the total amount of bleeding and the transfusion during and after the surgery. Our study aims at correcting the coagulopathy from massive bleeding and transfusion during distraction osteotomy using continuous infusion of antifibrinolytic agent, tranexamic acid. Tranexamic acid infusion is determined according to the pharmacokinetic model, and the changes in coagulopathy will be defined using thromboelastography.

02

Conditions studied

  • Craniosynostosis Patients Undergoing Distraction Osteotomy

Browse trials for

Keywords

  • Tranexamic acid
  • pharmacokinetics
  • craniosynostosis
03

In context

Craniosynostoses

51 studies on the registry are indexed under Craniosynostoses; 14 are open to participants now.

This study's enrollment of 50 is above the median of 27 across 22 interventional studies indexed under Craniosynostoses.

Browse Craniosynostoses studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,418 studies on the registry; 241 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients scheduled for distraction osteostomy under the diagnosis of Craniosynostosis.
  2. Patients aged from 2 months to 6 years, either of whose patients had consented
  3. 1 or 2

Exclusion criteria

Exclusion Criteria:

  1. Coagulopathy with either PT > 1.5 or \< 50,000/dL
  2. Patients took any NSAIDs within 2 days, or aspirin within 14 days prior to surgery
  3. History of convulsive seizure, epilepsy, any brain surgery
  4. Known drug allergic reaction to tranexamic acid
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Control

    Drug: normal saline

  • Experimental
    Tranexamic acid

    Drug: Tranexamic Acid

Interventions

  • 10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr

  • Drugnormal saline

    10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr

06

What researchers measure

Primary outcomes

  1. Bleeding loss

    Assessing the amount of bleeding during each intraop hours, and postoperative periods.

    Time frame: from every each hour during intraop, periodImmediate postop, postoperative 24hr to postoperative 48hr

07

Study locations

1 site
  • Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine
    Seoul, 120-752, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02180321
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jul 2, 2014
Start date
Jun 2013
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Apr 12, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion